WALTHAM, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that it will present at the following investor conferences:
Cantor Global Healthcare Conference 2025
Fireside Chat Date: Wednesday, September 3, 2025
Fireside Chat Time: 2:10 PM ET
Location: New York, NY
H.C. Wainwright 27th Annual Global Investment Conference
Fireside Chat Date: Monday, September 8, 2025
Fireside Chat Time: 12:00 PM ET
Location: New York, NY
Live webcasts of the fireside chats will be available in the investor section of the company’s website at investors.invivyd.com and will be archived for approximately 30 days following each event.
In addition to the fireside chats, the management team will host investor meetings at the conferences. Investors participating in the conferences who are interested in meeting with Invivyd management should contact their Cantor or H.C. Wainwright representative.
About Invivyd
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more.
Contacts:
Media Relations
(781) 208-1747
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations
(781) 208-1747
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.06 |
| Daily Change: | 0.09 8.94 |
| Daily Volume: | 2,527,232 |
| Market Cap: | US$221.940M |
August 22, 2025 August 20, 2025 August 14, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
